# 人狂犬病疫苗市场 > 人狂犬病疫苗市场研究报告按疫苗类型（灭活病毒疫苗、改良活病毒疫苗、重组疫苗）、按给药途径（肌肉注射、皮内注射、皮下注射）、按免疫球蛋白（人狂犬病免疫球蛋白（HRIG）、马狂犬病免疫球蛋白（ERIG））、按应用（暴露前预防、暴露后预防）、按剂型（小瓶、预填充注射器）和按地区（北美、欧洲、南美、亚太、中东和非洲） - 增长与行业预测2025至2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.98% - **2024:** $ 0.62 Billion - **2025:** $ 0.67 Billion - **2035:** $ 1.31 Billion - **Key Players:** Companies such as Sanofi(FR), Bharat Biotech (IN), Merck & Co. (US), GlaxoSmithKline (GB), Serum Institute of India (IN), Pfizer (US), Haffkine Bio-Pharmaceutical Corporation (IN), Zydus Cadila (IN) are some of the major participants in the global market. **Report ID:** MRFR/Pharma/28928-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026 **URL:** https://www.marketresearchfuture.com/reports/human-rabies-vaccine-market-30685 --- ## Market Summary ## **Human Rabies Vaccine Market Overview** As per MRFR analysis, the Human Rabies Vaccine Market Size was estimated at 0.62 (USD Billion) in 2024. The Human Rabies Vaccine Market Industry is expected to grow from 0.67 (USD Billion) in 2025 to 1.23 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.98% during the forecast period (2025 - 2034). ### **Key Human Rabies Vaccine Market Trends Highlighted** Globally, the human rabies vaccine market exhibits promising growth prospects. Key market drivers include increasing awareness about rabies prevention and vaccination, expanding immunization programs in developing regions, and the rise in animal-borne diseases. Governments and non-profit organizations are actively involved in promoting rabies awareness campaigns, which has contributed to the increased demand for vaccines. Additionally, technological advancements, such as the development of new vaccine formulations and delivery methods, are creating opportunities for market growth. In recent times, trends in the human rabies vaccine market include the emergence of needle-free vaccination systems, advancements in vaccine storage and transportation, and the rising focus on personalized vaccination approaches tailored to specific population groups. The market is expected to witness continued growth in the coming years due to these factors, providing opportunities for manufacturers and suppliers to expand their offerings and cater to the evolving needs of the market. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Human Rabies Vaccine Market Drivers** ### **Increasing Incidence of Rabies** Rabies is a fatal viral disease that affects the central nervous system. It is transmitted through the bite of an infected animal, most commonly dogs. The World Health Organization (WHO) estimates that rabies causes approximately 59,000 deaths each year, primarily in Asia and Africa. The increasing incidence of rabies is a major driver of the Human Rabies Vaccine Market. The rising number of rabies cases is due to several factors, including the growing population of stray dogs, the lack of access to rabies vaccination in some regions, and the increasing movement of people and animals across borders. As the incidence of rabies continues to rise, the demand for human rabies vaccines is expected to grow. ### **Growing Awareness of Rabies Prevention** The growing awareness of rabies prevention is another major driver of the Human Rabies Vaccine Market. Public health campaigns and educational programs have helped to raise awareness of the importance of rabies vaccination. As more people become aware of the risks of rabies and the benefits of vaccination, the demand for human rabies vaccines is expected to increase. The Human Rabies Vaccine Market Industry includes key players such as Sanofi Pasteur, Merck & Co., Inc., and GSK. ### **Government Initiatives to Control Rabies** Government initiatives to control rabies are also driving the growth of the Human Rabies Vaccine Market. Many governments have implemented mandatory rabies vaccination programs for dogs and other animals. These programs have helped to reduce the incidence of rabies in some regions. However, rabies remains a major problem in many developing countries, where access to rabies vaccination is limited. As governments continue to implement rabies control programs, the demand for human rabies vaccines is expected to increase in these regions. ## **Human Rabies Vaccine Market Segment Insights** ### **Human Rabies Vaccine Market Vaccine Type Insights** The market is segmented based on vaccine type into killed virus vaccine, modified live virus vaccine, and recombinant vaccine. Killed Virus Vaccine: Killed virus vaccines are produced by inactivating the rabies virus using chemicals or heat. They are the most commonly used type of rabies vaccine and are highly effective in preventing the disease. Killed virus vaccines are generally well-tolerated and have a low risk of side effects. Modified Live Virus Vaccine: Modified live virus vaccines are produced by weakening the rabies virus in the laboratory. They are less commonly used than killed virus vaccines but are generally more effective in preventing rabies. Modified live virus vaccines can cause more side effects than killed virus vaccines, but these side effects are usually mild. Recombinant Vaccine: Recombinant vaccines are produced using genetic engineering techniques. They are the newest type of rabies vaccine and are highly effective in preventing the disease. Recombinant vaccines are generally well-tolerated and have a low risk of side effects. The killed virus vaccine segment held the largest share of the Human Rabies Vaccine Market in 2023 due to its widespread use and high efficacy. However, the modified live virus vaccine segment is expected to grow at a faster CAGR during the forecast period due to its increased effectiveness and lower risk of side effects. The recombinant vaccine segment is also expected to grow at a significant CAGR during the forecast period due to its high efficacy and low risk of side effects. Overall, the Human Rabies Vaccine Market is expected to grow at a steady pace during the forecast period, driven by the increasing demand for rabies vaccines in developing countries and the development of new and more effective vaccines. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Human Rabies Vaccine Market Route of Administration Insights** #### **Intramuscular Injection** Intramuscular Injection accounted for the largest revenue share in 2023. Intramuscular Injection is the most common route of administration for rabies vaccines. It is a safe and effective way to deliver the vaccine to the body. The vaccine is injected into the muscle, where it is absorbed into the bloodstream. #### **Intradermal Injection** Intradermal Injection is another common route of administration for rabies vaccines. It is less painful than intramuscular injection, but it is not as effective. The vaccine is injected into the skin, where it is absorbed into the bloodstream. #### **Subcutaneous Injection** Subcutaneous Injection is the least common route of administration for rabies vaccines. It is less painful than intramuscular injection, but it is not as effective. The vaccine is injected under the skin, where it is absorbed into the bloodstream. ### **Human Rabies Vaccine Market Immunoglobulins Insights** Immunoglobulins, comprising Human Rabies Immunoglobulin (HRIG) and Equine Rabies Immunoglobulin (ERIG), play a crucial role in the Human Rabies Vaccine Market. HRIG, derived from human plasma, offers high potency and a low risk of allergic reactions. ERIG, obtained from horse serum, is a more cost-effective option. In 2023, the Immunoglobulins segment held a significant market share, valued at approximately USD 0.29 billion. It is projected to grow at a CAGR of 6.98%, reaching an estimated USD 0.51 billion by 2032. The rising incidence of rabies, particularly in developing countries, coupled with increased awareness and vaccination programs, is driving market growth. Additionally, the development of new and improved immunoglobulin formulations is expected to further boost segment expansion ### **Human Rabies Vaccine Market Application Insights** The Human Rabies Vaccine Market size for Pre-Exposure Prophylaxis is expected to grow from an estimated USD 0.36 billion in 2023 to USD 0.58 billion by 2032, at a CAGR of 6.1%. The Human Rabies Vaccine Market size for Post-Exposure Prophylaxis is expected to grow from USD 0.19 billion in 2023 to USD 0.43 billion by 2032, at a CAGR of 7.6%. The market growth is attributed to the increasing incidence of rabies, the rising awareness of rabies prevention, and the availability of effective vaccines. The Pre-Exposure Prophylaxis segment is expected to hold a larger market share due to the increasing adoption of pre-exposure vaccination among travelers, healthcare workers, and individuals living in endemic areas. The Post-Exposure Prophylaxis segment is expected to experience significant growth due to the rising incidence of animal bites and the need for immediate post-exposure treatment. ### **Human Rabies Vaccine Market Dosage Form Insights** The Human Rabies Vaccine Market is segmented by Dosage Form into Vials and Pre-Filled Syringes. Among these, the Vials segment held a larger market share in 2023, owing to the widespread availability and ease of administration of vials in various healthcare settings. However, the Pre-Filled Syringes segment is anticipated to exhibit a higher growth rate during the forecast period. The growing adoption of pre-filled syringes for subcutaneous administration and the increasing convenience they offer in terms of accurate dosing and ease of handling are driving the growth of this segment. In 2023, the Human Rabies Vaccine Market for Vials was valued at 0.31 USD Billion, and it is projected to reach 0.49 USD Billion by 2032, exhibiting a CAGR of 6.04%. The Pre-Filled Syringes segment, valued at 0.24 USD Billion in 2023, is estimated to reach 0.52 USD Billion by 2032, growing at a CAGR of 8.37%. ### **Human Rabies Vaccine Market Regional Insights** North America dominated the market share in 2023, owing to the presence of a well-established healthcare infrastructure, a high incidence of rabies cases, and favorable government initiatives for rabies prevention and control. Europe is projected to experience steady growth due to increasing awareness about rabies and government initiatives to eliminate the disease. APAC is expected to witness the fastest growth, driven by rising healthcare expenditure, growing population, and increasing urbanization. South America and MEA are anticipated to contribute significantly to the market growth due to rising disposable income and improving healthcare access. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Human Rabies Vaccine Market Key Players and Competitive Insights** Major players in the Human Rabies Vaccine Market industry are constantly involved in R&D activities to develop innovative and more effective vaccines. Leading Human Rabies Vaccine Market players are focused on expanding their product portfolio through strategic collaborations, partnerships, and acquisitions. The Human Rabies Vaccine Market is highly competitive, with several key players accounting for a significant market share. These players are investing heavily in research and development to develop more advanced and effective vaccines. They are also expanding their geographic reach through strategic partnerships and collaborations. Sanofi Pasteur, a leading company in the Human Rabies Vaccine Market, is committed to providing innovative and high-quality vaccines to prevent rabies. The company's rabies vaccine, RabAvert, is a highly effective vaccine that has been used to protect millions of people worldwide. Sanofi Pasteur is also actively involved in research and development to develop new and improved rabies vaccines. Another key player in the Human Rabies Vaccine Market is Bavarian Nordic. The company's rabies vaccine, Rabipur, is a well-established and widely used vaccine that has been shown to be safe and effective. Bavarian Nordic is also developing a next-generation rabies vaccine that is expected to provide even better protection against the virus. ### **Key Companies in the Human Rabies Vaccine Market Include** - Biofabri - Serum Institute of India Ltd - Sanofi Pasteur - Incepta Vaccine - Hunan Changde BioPharmaceutical - Bharat Biotech International Ltd - GSK - Bavarian Nordic - [Pfizer](https://www.pfizer.com/products/product-list) - Pasteur Institute of Korea - Sinovac Biotech - Chengda Biopharm - Bio Farma - Abbott Laboratories - J/Merck Sharp Dohme ## **Human Rabies Vaccine Market Industry Developments** Key factors driving growth include increasing awareness of rabies prevention, expanding vaccination programs, and technological advancements in vaccine development. Recent developments include the introduction of more effective and affordable rabies vaccines, such as the vero cell rabies vaccine. Furthermore, strategic collaborations and partnerships between pharmaceutical companies and research institutions are fostering innovation and expanding market reach. Governments worldwide are prioritizing rabies control measures, leading to increased demand for human rabies vaccines. ## **Human Rabies Vaccine Market Segmentation Insights** ### **Human Rabies Vaccine Market Vaccine Type Outlook** - Killed Virus Vaccine - Modified Live Virus Vaccine - Recombinant Vaccine ### **Human Rabies Vaccine Market Route of Administration Outlook** - Intramuscular Injection - Intradermal Injection - Subcutaneous Injection ### **Human Rabies Vaccine Market Immunoglobulins Outlook** - Human Rabies Immunoglobulin (HRIG) - Equine Rabies Immunoglobulin (ERIG) ### **Human Rabies Vaccine Market Application Outlook** - Pre-Exposure Prophylaxis - Post-Exposure Prophylaxis ### **Human Rabies Vaccine Market Dosage Form Outlook** - Vials - Pre-Filled Syringes ### **Human Rabies Vaccine Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Increased Travel and Migration 国际旅行和移民的增加可能会影响人类狂犬病疫苗市场。随着人们前往狂犬病流行的地区，暴露风险增加，促使旅行者在出行前寻求接种疫苗。这一趋势在冒险旅行者和可能接触野生动物或流浪动物的外籍人士中尤为明显。 因此，预防接种狂犬病疫苗的需求预计将上升，推动市场增长。此外，随着移民模式的变化，公共卫生当局可能会实施疫苗接种计划，以保护脆弱人群，进一步促进市场的扩展。 - 联合国人口基金报告全球有超过2.81亿国际移民，而疾病控制与预防中心强调在超过150个国家存在狂犬病风险，支持旅行者和流动人群对预防接种的需求增加。 ### Rising Incidence of Rabies Cases 各地区狂犬病病例的增加似乎是人类狂犬病疫苗市场的主要驱动因素。根据世界卫生组织的数据，狂犬病每年导致约59,000人死亡，主要发生在发展中国家。这一令人担忧的统计数据突显了有效疫苗接种计划的迫切需求。随着人们对动物咬伤传播狂犬病的认识提高，公共卫生倡议可能会强调疫苗接种作为预防措施。 因此，对狂犬病控制的高度关注可能会导致人类狂犬病疫苗需求的增加，从而推动市场增长。此外，某些地区狂犬病病例的增加可能促使政府和卫生组织将更多资源分配给疫苗接种活动，进一步刺激市场。 - 世界卫生组织估计每年有59,000人死于狂犬病，其中95%发生在非洲和亚洲，而健康指标与评估研究所指出流行地区的疾病负担持续存在，强化了全球对疫苗接种和预防倡议的强烈需求。 ### Government Initiatives and Funding 旨在消灭狂犬病的政府倡议可能会显著影响人类狂犬病疫苗市场。各国实施了国家狂犬病控制计划，这些计划通常包括针对人类和动物的疫苗接种策略。例如，泛美卫生组织报告称，在拉丁美洲的狂犬病疫苗接种活动中进行了大量投资。 这些倡议不仅增强了公共卫生，还为疫苗制造商创造了良好的环境。对狂犬病预防计划的资金增加可能会导致疫苗获取的扩大，从而推动市场增长。此外，政府与非政府组织之间的合作可以促进在服务不足地区的疫苗分发，进一步增强市场。 - 泛美卫生组织报告称，美洲每年进行超过1亿次犬只疫苗接种，而全球艾滋病、结核病和疟疾基金支持综合疾病控制资金模型，加强大规模免疫接种计划，提高流行地区的疫苗可及性。 ### Growing Veterinary Vaccination Programs 兽医疫苗接种计划的扩展预计将对人类狂犬病疫苗市场产生积极影响。随着宠物拥有率的增加和对人畜共患病的认识提高，越来越多的宠物主人可能会为他们的动物接种狂犬病疫苗。这种主动的做法不仅保护了宠物，还减少了狂犬病传播给人类的风险。 因此，随着社区认识到群体免疫的重要性，人类狂犬病疫苗的需求可能会上升。此外，兽医和人类健康部门之间的合作可以增强疫苗接种工作，产生协同效应，惠及市场。 - 世界卫生组织表示，接种70%的犬只可以消除狂犬病传播，而无国界医生组织强调社区基础的疫苗接种活动每年覆盖数千人，显著降低人畜共患病传播风险，支持人类疫苗的需求。 ### Technological Innovations in Vaccine Production 疫苗生产中的技术进步有望改变人类狂犬病疫苗市场。重组DNA技术和改进的佐剂等创新有潜力提高疫苗的有效性和安全性。这些进展可能导致开发出更有效的疫苗，所需剂量更少，从而提高患者的依从性。 此外，更高效的疫苗生产能力可能降低成本，使其更易于接触到高风险人群。随着制造商采用这些尖端技术，市场可能会出现产品供应的激增，以满足多样化的消费者需求和偏好。 - 全球疫苗联盟自2000年以来支持超过9.81亿儿童的免疫接种，而联合国儿童基金会每年采购超过20亿剂疫苗，展示了规模效益，使得全球先进、成本效益高的狂犬病疫苗生产和分发成为可能。 ## Future Outlook 人狂犬病疫苗市场规模预计到2035年将达到13.12亿美元，年均增长率为6.98%，这得益于意识的提高、狂犬病发病率的上升以及疫苗技术的进步。 **New opportunities:** - 扩大疫苗咨询的远程医疗服务 开发组合疫苗以实现更广泛的疾病预防 与兽医服务合作开展社区疫苗接种项目 到2035年，市场预计将实现强劲增长，巩固其在全球健康中的地位。 ## Segment Insights ### 按类型：灭活病毒疫苗（最大）与重组疫苗（增长最快） 在人用狂犬病疫苗市场中，灭活病毒疫苗目前在各种类型中占据59%的最大市场份额。由于其长期的有效性和在人类及兽医应用中的广泛接受，这种经典疫苗已确立了其主导地位。改良活病毒疫苗也占据了市场的相当部分，但其份额正逐渐被对重组疫苗日益增长的偏好所掩盖。市场分析师注意到，市场正在向结合安全性和有效性的创新解决方案转变，以预防狂犬病。市场的增长趋势主要受到对狂犬病预防意识的提高和疫苗技术进步的推动。重组疫苗尤其迅速崛起，因为消费者和医疗提供者寻求更安全、更有效的疫苗接种选择。随着对减少不良反应的关注，同时保持高效能，重组疫苗的趋势表明医疗行业向创新和以患者为中心的解决方案的大规模运动。 疫苗类型：灭活病毒（主导）与重组（新兴） 灭活病毒疫苗被视为市场中的主导部分，因为其安全性和有效性的良好记录。它通常由已被杀死或灭活的病毒颗粒制成，使其无法引起疾病，同时仍能引发强烈的免疫反应。这种类型的疫苗因其在狂犬病预防中的可靠性而受到青睐，尤其是在动物中以及人类接触狂犬病的情况下。另一方面，重组疫苗代表了新兴部分，展示了由生物技术进步驱动的创新。它们被设计用于产生狂犬病病毒的特定抗原，从而降低不良反应的可能性并改善免疫反应。向重组疫苗的转变表明市场正在发展，以应对现代健康挑战和消费者期望。 ### 按给药途径：肌肉注射（最大）与皮内注射（增长最快） 在人用狂犬病疫苗市场中，各种给药途径的市场份额分布显示，肌肉注射占据了64%的最大份额，这得益于其长期的接受度和在疫苗投放中的有效性。紧随其后，皮内注射在新兴市场中获得了关注，因其潜在的低剂量需求和改善患者舒适度而受到青睐。皮下注射虽然也相关，但占据的份额较小，并且与其他方法相比，面临独特的挑战，影响其采用。 给药方法：肌肉注射（主导）与皮内注射（新兴） 肌肉注射仍然是市场中主导的给药方法，因其已确立的有效性、易于施用和在各种医疗环境中的广泛接受。然而，皮内注射正在强劲崛起，因其优势如需要更小的疫苗量和增强免疫反应而受到认可。随着医疗提供者越来越寻求优化疫苗分发和患者体验，这种方法的吸引力在增长，特别是在资源有限的地区。皮内技术的灵活性和创新应用正在激发兴趣和投资，可能重塑市场格局。 ### 按免疫球蛋白：HRIG（最大）与ERIG（增长最快） 在人用狂犬病疫苗市场中，免疫球蛋白类型的分布展示了人狂犬病免疫球蛋白（HRIG）的明显主导地位，其市场份额占62%。这一部分已建立并广泛认可，因其在狂犬病暴露后预防中的有效性。同时，马狂犬病免疫球蛋白（ERIG）虽然使用不如广泛，但由于其成本效益和某些临床应用，正在获得关注，推动其在特定人群中的采用。 免疫球蛋白：HRIG（主导）与ERIG（新兴） 人狂犬病免疫球蛋白（HRIG）在免疫球蛋白部分中仍然是主导者，因其已确立的安全性和有效性，使其成为狂犬病暴露后治疗的首选。HRIG源自人类血浆，提供了较低的过敏反应风险和增强的患者安全性。另一方面，马狂犬病免疫球蛋白（ERIG）正在市场中崭露头角，吸引寻求成本效益替代方案的医疗提供者。尽管ERIG可能带来更高的不良反应风险，但其在特定情况下的可负担性和有效性促进了其在资源有限地区的接受度。 ### 按应用：暴露后预防（最大）与暴露前预防（增长最快） 在人用狂犬病疫苗市场中，应用部分主要分为两类：暴露前预防和暴露后预防。暴露后预防部分占据67%的最大市场份额，因其在管理潜在狂犬病感染方面的关键作用。另一方面，暴露前预防因在高风险地区的意识提高和疫苗接种活动而获得关注，推动其市场存在的增长。 应用：暴露后预防（主导）与暴露前预防（新兴） 暴露后预防（PEP）被认为是市场中的主导应用，主要用于在潜在狂犬病暴露后进行有效的疾病预防。该部分受益于强调及时接种的强大医疗协议和公共卫生倡议。相反，暴露前预防（PrEP）正在迅速崛起，因对地方性地区狂犬病威胁的意识提高以及旅行者和高风险专业人士采取的主动措施。PEP作为反应措施，而PrEP则专注于预防，创造了市场增长中的动态互动，因为这两个部分满足不同但重叠的人群需求。 ### 按剂型：瓶（最大）与预填充注射器（增长最快） 人用狂犬病疫苗市场主要由瓶驱动，目前在该部分占据61%的最大份额。瓶因其在疫苗投放中的传统使用而受到青睐，并在医疗界广泛接受。其已建立的存在确保了稳定的需求，并在全球各地的市场中占据强大的立足点。相比之下，预填充注射器虽然占据较小的市场份额，但因其便利性和易于施用而迅速获得关注，特别是在优先考虑快速反应时间的环境中。市场的增长趋势表明，随着医疗提供者寻求高效的疫苗接种方法，向预填充注射器的显著转变。预填充注射器提供的便利性减少了准备时间并降低了污染风险，与旨在提高疫苗接种率的公共卫生倡议相一致。此外，注射器技术的进步和对狂犬病预防意识的提高正在推动对这些新兴剂型的需求，使其成为未来狂犬病疫苗接种策略的重要组成部分。 瓶（主导）与预填充注射器（新兴） 瓶长期以来一直是市场中的主导剂型，为医疗提供者提供可靠的储存和易于使用的优势。它们通常设计用于多剂量，不仅有助于资源优化，还提供了灵活的接种时间表。然而，预填充注射器的出现值得注意；由于预先测量的剂量和降低感染风险等特性，它们正在获得越来越多的欢迎。其设计确保疫苗更高效地施用，使疫苗接种活动中的反应更快。因此，尽管瓶仍然至关重要，但预填充注射器代表了狂犬病疫苗接种的未来，将可及性和简化的施用作为市场演变的驱动力。 ## Regional Market Share Analysis ### 北美：疫苗市场的领导者 北美在2024年的人用狂犬病疫苗市场规模领先，占全球收入的32.26%以上。该地区的增长受到对狂犬病预防意识的提高、严格的监管框架和强大的医疗保健基础设施的推动。对狂犬病疫苗的需求进一步受到宠物拥有率上升和野生动物中狂犬病流行的推动，促使公共卫生倡议推广疫苗接种。 美国和加拿大是该地区的领先国家，默克公司和辉瑞等主要制药公司积极参与疫苗生产。竞争格局以创新和关键参与者之间的战略合作为特征，确保有效疫苗的稳定供应。先进的研究设施和疫苗开发的资金也有助于该地区在市场中的主导地位。 增长受到强大的免疫基础设施、高意识水平和监管机构支持的先进疫苗开发的推动。疾病控制与预防中心(CDC)报告称，由于广泛的疫苗接种和暴露后预防治疗的可用性，美国的狂犬病死亡人数每年少于10例。这一强有力的预防框架支持了该地区对疫苗的持续需求和创新。 ### 欧洲：监管框架推动增长 欧洲人用狂犬病疫苗市场规模在2024年估计为1.86亿美元，使其成为第二大区域市场，市场份额为30%。该地区受益于强大的监管支持和旨在预防狂犬病的公共卫生倡议。德国和法国等国家处于前沿，日益增加的疫苗接种活动和意识项目促进了市场扩展。 欧洲药品管理局(EMA)在确保疫苗安全性和有效性方面发挥着关键作用，进一步增强了消费者信心。欧洲的主要国家包括德国、法国和英国，赛诺菲和葛兰素史克等主要参与者积极参与疫苗开发。竞争格局以公共卫生组织和私营公司之间的合作为特征，增强了疫苗的可及性。先进的医疗保健系统和研究项目的资金也支持了该地区狂犬病疫苗市场的增长。 增长受到强大的监管框架、协调的疫苗接种计划和日益增加的公共卫生倡议的推动。根据世界卫生组织(WHO)的说法，欧洲通过大规模疫苗接种和监测计划显著减少了狂犬病的发生，许多国家实现了近乎消除。对疫苗接种策略的持续投资支持了人用狂犬病疫苗的稳定需求。 ### 亚太地区：新兴市场潜力 亚太地区正在成为人用狂犬病疫苗的重要市场，占全球市场份额的约25%。该地区的增长受到狂犬病发生率上升的推动，特别是在印度和中国等国家，公共卫生活动正在加大力度。监管机构也在关注改善疫苗的可及性和可负担性，这对于控制人口稠密地区的狂犬病暴发至关重要。 印度和中国是该地区的领先国家，巴拉特生物技术和印度血清研究所等关键参与者在疫苗生产中做出了重要贡献。竞争格局正在演变，本地制造商正在增加市场份额。政府机构与私营部门之间的合作正在促进创新，并确保稳定的疫苗供应，以满足该地区日益增长的需求。 ### 中东和非洲：挑战与机遇 中东和非洲地区对人用狂犬病疫苗的需求日益增长，占全球市场份额的约5%。狂犬病病例的增加，特别是在农村地区，推动了对有效疫苗接种计划的需求。监管挑战和有限的医疗基础设施构成了重大障碍，但世界卫生组织等组织的倡议正在改善疫苗分发和意识。 南非和尼日利亚等国在狂犬病疫苗接种工作中处于前沿，当地制造商与国际组织合作，增强疫苗的可用性。竞争格局以本地和全球参与者的混合为特征，重点是增加公共卫生倡议。该地区独特的挑战为狂犬病疫苗开发提供了创新和投资的机会。 ## Competitive Benchmarking 人用狂犬病疫苗市场的特点是竞争格局日益受到创新、战略合作伙伴关系和区域扩展的影响。赛诺菲(FR)、默克公司(US)和印度血清研究所(IN)等关键参与者处于前沿，各自采用不同的策略来增强市场存在感。赛诺菲(FR)专注于利用其广泛的研究能力开发下一代疫苗，而默克公司(US)则强调与地方卫生当局的战略合作，以改善疫苗的可及性。另一方面，印度血清研究所(IN)专注于扩大生产，以满足日益增长的全球需求，特别是在新兴市场。 这些策略共同促进了一个动态的竞争环境，其中创新和可及性至关重要。在商业战术方面，各公司越来越多地本地化生产，以降低成本并提高供应链效率。这种方法在狂犬病高发地区特别有效，当地生产可以显著降低分发挑战。市场结构适度分散，多个参与者争夺市场份额，但大型公司的影响仍然显著。他们优化供应链和本地化生产的能力可能会在未来几年塑造竞争动态。2025年8月，默克公司(US)宣布与一家领先的非营利组织建立合作伙伴关系，以增强在非洲农村地区的狂犬病疫苗接种活动。 这一战略举措具有重要意义，因为它不仅扩大了默克在服务不足市场的覆盖范围，还与全球健康倡议相一致，旨在消灭狂犬病。通过与地方组织合作，默克可能会改善疫苗分发和意识，从而提升其品牌声誉和市场份额。2025年9月，赛诺菲(FR)推出了一种新的狂犬病疫苗配方，承诺减少有效免疫所需的剂量。这一创新至关重要，因为它解决了疫苗施用中的后勤挑战，特别是在偏远地区。这种配方的引入可能会导致疫苗接种率的提高，使赛诺菲在狂犬病预防工作中处于领先地位。 2025年7月，印度血清研究所(IN)将其生产能力扩大了30%，以满足对狂犬病疫苗日益增长的全球需求。这一扩展表明该公司致力于满足公共卫生需求，并可能增强其在市场中的竞争优势。通过增加生产能力，印度血清研究所可能会巩固其在国内和国际市场中的关键供应商地位。截至2025年10月，人用狂犬病疫苗市场正在见证强调数字化、可持续性和先进技术整合的趋势。各公司越来越多地形成战略联盟，以增强其运营能力和市场覆盖。竞争格局正在从以价格为基础的竞争转向优先考虑创新、技术进步和供应链可靠性。这一演变表明，未来的差异化将取决于提供高质量、可及疫苗的能力，同时保持运营效率。 ## Recent News & Developments 推动增长的关键因素包括对狂犬病预防意识的提高、疫苗接种计划的扩展以及疫苗开发中的技术进步。最近的发展包括推出更有效和更实惠的狂犬病疫苗，例如vero细胞狂犬病疫苗。 此外，制药公司与研究机构之间的战略合作与伙伴关系正在促进创新并扩大市场覆盖。全球各国政府正在优先考虑狂犬病控制措施，导致对人用狂犬病疫苗的需求增加。 ## Report Scope | 2024年市场规模 | 6.245(亿美元) | | --- | --- | | 2025年市场规模 | 6.681(亿美元) | | 2035年市场规模 | 13.12(亿美元) | | 复合年增长率(CAGR) | 6.98% (2025 - 2035) | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 亿美元 | | 关键公司简介 | 赛诺菲(FR)、巴拉特生物技术(IN)、默克公司(US)、葛兰素史克(GB)、印度血清研究所(IN)、辉瑞(US)、哈夫金生物制药公司(IN)、Zydus Cadila(IN) | | 覆盖的细分市场 | 疫苗类型、给药途径、免疫球蛋白、应用、剂型、区域 | | 关键市场机会 | 疫苗输送系统的进步提高了市场的可及性。 | | 关键市场动态 | 对预防性医疗的需求上升推动了市场的创新和竞争。 | | 覆盖的国家 | 北美、欧洲、亚太地区、南美、中东和非洲 | ## Frequently Asked Questions **Q: 截至2024年，人用狂犬病疫苗市场的当前估值是多少？** A: 该市场在2024年的估值为6.245亿美元。 **Q: 预计到2035年，人用狂犬病疫苗市场的市场估值是多少？** A: 预计到2035年，该市场将达到13.12亿美元。 **Q: 在2025年至2035年的预测期内，市场的预期年均增长率（CAGR）是多少？** A: 在预测期内，市场的预期年均增长率为6.98%。 **Q: 哪些公司被认为是人用狂犬病疫苗市场的关键参与者？** A: 关键参与者包括赛诺菲、巴拉特生物技术、默克公司、葛兰素史克、印度血清研究所、辉瑞、哈夫金生物制药公司和Zydus Cadila。 **Q: 人用狂犬病疫苗市场中有哪些不同类型的疫苗？** A: 该市场包括灭活病毒疫苗、改良活病毒疫苗和重组疫苗。 **Q: 市场的给药途径细分是如何划分的？** A: 给药途径细分包括肌肉注射、皮内注射和皮下注射。 **Q: 人用狂犬病疫苗市场中有哪些免疫球蛋白类型？** A: 该市场提供人用狂犬病免疫球蛋白（HRIG）和马用狂犬病免疫球蛋白（ERIG）。 **Q: 市场涵盖了哪些应用？** A: 应用包括暴露前预防和暴露后预防。 **Q: 人用狂犬病疫苗市场中有哪些剂型？** A: 该市场提供小瓶和预填充注射器作为剂型。 **Q: 2024年灭活病毒疫苗细分的估值是多少？** A: 2024年灭活病毒疫苗细分的估值为3.747亿美元。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/human-rabies-vaccine-market-30685*